Relmada Therapeutics, Inc.

NASDAQ:RLMD

3.26 (USD) • At close November 7, 2024
Bedrijfsnaam Relmada Therapeutics, Inc.
Symbool RLMD
Munteenheid USD
Prijs 3.26
Beurswaarde 98,367,892
Dividendpercentage 0%
52-weken bereik 1.88 - 7.223
Industrie Biotechnology
Sector Healthcare
CEO Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
Website https://www.relmada.com

An error occurred while fetching data.

Over Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for

Vergelijkbare Aandelen

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

1.78 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

9.46 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

2.51 USD

Pharvaris N.V. logo

Pharvaris N.V.

PHVS

22.32 USD

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

0.887 USD

Kiniksa Pharmaceuticals, Ltd. logo

Kiniksa Pharmaceuticals, Ltd.

KNSA

23.01 USD

Eagle Pharmaceuticals, Inc. logo

Eagle Pharmaceuticals, Inc.

EGRX

0.85 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)